Chemesis International Inc. (CADMD) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Chemesis International Inc. (CADMD) trades at $0.08. Chemesis International Inc. cultivates, manufactures, distributes, and retails cannabis products across California, Puerto Rico, and Colombia. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for CADMD: CADMD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CADMD against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on CADMD.
How is this calculated? →Chemesis International Inc. (CADMD) Healthcare & Pipeline Overview
Chemesis International Inc. operates within the cannabis industry, focusing on cultivation, manufacturing, distribution, and retail of cannabis products. With operations spanning California, Puerto Rico, and Colombia, the company specializes in diverse extraction techniques, positioning itself to capitalize on the expanding global cannabis market amid evolving regulatory landscapes.
What Is the Investment Thesis for CADMD?
Chemesis International Inc. presents a speculative investment opportunity within the high-growth cannabis sector. The company's vertically integrated operations, spanning cultivation to retail, offer potential for margin expansion and revenue synergies. Key value drivers include successful expansion into new markets, optimization of extraction processes, and development of innovative cannabis products. Growth catalysts include evolving cannabis regulations in key markets and increasing consumer acceptance of cannabis products. Potential risks include intense competition, regulatory uncertainties, and capital constraints. Investors should carefully assess the company's ability to execute its growth strategy and navigate the evolving cannabis landscape. The company's OTC listing introduces additional risk factors that should be considered.
Based on FMP financials and quantitative analysis
CADMD Key Highlights
Chemesis International Inc. operates in the rapidly growing cannabis industry, projected to reach multi-billion dollar market size by 2030.
- The company's vertically integrated business model allows for control over the entire value chain, potentially improving margins.
- Chemesis has operations in California, Puerto Rico, and Colombia, providing geographic diversification.
- The company specializes in various extraction methods, enabling the creation of diverse cannabis products.
- Chemesis focuses on both recreational and medicinal cannabis markets, targeting a broad customer base.
Who Are CADMD's Competitors?
CADMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACB Aurora Cannabis Inc. | $3.81 | -2.56% | $236M | 55 |
| CGC Canopy Growth Corporation | $1.04 | +0.48% | $441M | 46 |
| TLRY Tilray Brands, Inc. | $4.67 | -3.31% | $522M | 47 |
| ZTS Zoetis Inc. | $75.44 | -1.62% | $31.6B | 85 |
| ITCI ITCI | $131.87 | +0.00% | $14.1B | 63 |
| ESALF Eisai Co., Ltd. | $29.90 | +0.00% | $8.44B | 61 |
| LNTH Lantheus Holdings, Inc. | $100.24 | -0.24% | $6.53B | 88 |
| AMRX Amneal Pharmaceuticals, Inc. | $17.90 | -1.16% | $5.72B | 65 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CADMD's Key Strengths?
Vertically integrated operations.
- Diverse product offerings.
- Strategic geographic presence.
- Expertise in various extraction methods.
What Are CADMD's Weaknesses?
Limited financial resources.
- Dependence on regulatory approvals.
- Intense competition.
- OTC market listing.
What Could Drive CADMD Stock Higher?
Potential changes in cannabis regulations in key markets could create new opportunities for Chemesis.
- Increasing consumer acceptance of cannabis products is driving demand and revenue growth.
- Development and launch of new cannabis-infused products could attract new customers.
- Expansion into new markets could increase revenue and market share.
What Are the Key Risks for CADMD?
Regulatory changes could negatively impact Chemesis's operations and profitability.
- Intense competition in the cannabis industry could erode market share and margins.
- Price volatility in the cannabis market could impact revenue and profitability.
- Capital constraints could limit Chemesis's ability to expand and invest in new products.
- OTC market listing introduces additional risks related to liquidity and disclosure.
What Are the Growth Opportunities for CADMD?
- Expansion into new markets: Chemesis can expand its operations into additional states and countries as cannabis legalization progresses. The global cannabis market is projected to reach $100 billion by 2030, offering significant growth potential. Successful expansion requires navigating complex regulatory frameworks and establishing strategic partnerships. Timeline: Ongoing.
- Development of innovative products: Chemesis can develop new cannabis-infused products to cater to evolving consumer preferences. The market for cannabis edibles, beverages, and topicals is growing rapidly. Innovation requires investment in research and development and effective marketing strategies. Timeline: Ongoing.
- Optimization of extraction processes: Chemesis can improve its extraction processes to increase efficiency and reduce costs. Advanced extraction technologies can enhance product quality and consistency. Optimization requires investment in new equipment and training. Timeline: Ongoing.
- Strategic partnerships: Chemesis can form strategic partnerships with other companies in the cannabis industry to expand its reach and capabilities. Partnerships can provide access to new markets, technologies, and distribution channels. Timeline: Ongoing.
- Focus on medical cannabis: Chemesis can focus on the medical cannabis market, which offers higher margins and greater regulatory certainty. The medical cannabis market is driven by increasing research into the therapeutic benefits of cannabis. Timeline: Ongoing.
What Are CADMD's Competitive Advantages?
- Vertically integrated operations provide cost advantages and control over the supply chain.
- Diverse product offerings cater to a broad customer base.
- Strategic geographic presence in key cannabis markets.
- Expertise in various extraction methods.
What Does CADMD Do?
Chemesis International Inc., established in 2013 and headquartered in Vancouver, Canada, is a vertically integrated cannabis company. It operates across multiple segments of the cannabis value chain, including cultivation, manufacturing, distribution, and retail. The company's geographic footprint extends to California, Puerto Rico, and Colombia, allowing it to serve diverse consumer markets. Chemesis specializes in various extraction methods, such as BHO extraction, alcohol extraction, and CO2 extraction, enabling the creation of a wide range of cannabis products. These products cater to both recreational and medicinal users. The company aims to establish a strong presence in key cannabis markets by focusing on quality, innovation, and strategic partnerships. Chemesis navigates the complex regulatory environment of the cannabis industry to ensure compliance and sustainable growth. The company's commitment to innovation and operational efficiency drives its competitive advantage in the evolving cannabis landscape.
What Products and Services Does CADMD Offer?
- Cultivates cannabis plants in California, Puerto Rico, and Colombia.
- Manufactures cannabis products using various extraction methods.
- Distributes cannabis products to retail outlets.
- Retails cannabis products through its own stores and online channels.
- Specializes in BHO extraction, alcohol extraction, and CO2 extraction.
- Develops and markets cannabis-infused products.
How Does CADMD Make Money?
- Vertically integrated operations, spanning cultivation to retail.
- Revenue generated from the sale of cannabis products.
- Focus on both recreational and medicinal cannabis markets.
What Industry Does CADMD Operate In?
Chemesis International Inc. operates within the rapidly evolving cannabis industry, characterized by increasing legalization and growing consumer acceptance. The market is highly competitive, with numerous players vying for market share. Key trends include the rise of cannabis-infused products, the expansion of retail channels, and the increasing focus on product quality and safety. Chemesis aims to differentiate itself through its vertically integrated operations, diverse product offerings, and strategic geographic presence. The company faces competition from both established cannabis companies and new entrants, requiring continuous innovation and operational efficiency to maintain a competitive edge.
Who Are CADMD's Key Customers?
- Recreational cannabis users.
- Medical cannabis patients.
- Retail dispensaries.
- Wholesale distributors.
Company Profile
Chemesis International Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Amandeep Singh Parmar.
CADMD Financials
Bull Case vs Bear Case
Bull Case
- Vertically integrated operations.
- Diverse product offerings.
- Strategic geographic presence.
- Expertise in various extraction methods.
Bear Case
- Limited financial resources.
- Dependence on regulatory approvals.
- Intense competition.
- OTC market listing.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
CADMD Latest News
No recent news available for CADMD.
CADMD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CADMD.
Price Targets
Wall Street price target analysis for CADMD.
CADMD MoonshotScore
What does this score mean?
The MoonshotScore rates CADMD 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Amandeep Singh Parmar
CEO
Amandeep Singh Parmar serves as the Chief Executive Officer of Chemesis International Inc. His background includes experience in the cannabis industry, with a focus on strategic development and operational management. He has been involved in various aspects of the cannabis value chain, from cultivation to retail. Parmar's expertise lies in navigating the complex regulatory landscape and driving growth in the rapidly evolving cannabis market. His leadership aims to position Chemesis as a key player in the industry.
Track Record: Under Amandeep Singh Parmar's leadership, Chemesis International Inc. has focused on expanding its operations and developing new products. Key milestones include establishing a presence in California, Puerto Rico, and Colombia. Parmar has also overseen the implementation of various extraction methods and the development of cannabis-infused products. His strategic decisions aim to drive revenue growth and improve profitability.
CADMD OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Chemesis International Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on this tier may have limited financial disclosure, potentially increasing investment risk. Unlike NYSE or NASDAQ listings, which require strict adherence to financial and corporate governance standards, the OTC Other tier has minimal requirements, leading to greater information asymmetry and potential for speculative trading. Investors should exercise caution and conduct thorough due diligence before investing in companies on this tier.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Monitor the company's trading volume and price volatility.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investments.
- Company has been in operation since 2013.
- Operations in multiple geographic locations (California, Puerto Rico, Colombia).
- Focus on cultivation, manufacturing, distribution, and retail.
Chemesis International Inc. Healthcare Stock: Key Questions Answered
What does Chemesis International Inc. do?
Chemesis International Inc. is a vertically integrated cannabis company that cultivates, manufactures, distributes, and retails cannabis products. The company operates in California, Puerto Rico, and Colombia, focusing on both recreational and medicinal cannabis markets. Chemesis specializes in various extraction methods, including BHO, alcohol, and CO2 extraction, to create a diverse range of cannabis-infused products.
What do analysts say about CADMD stock?
As of March 16, 2026, formal analyst coverage of Chemesis International Inc. (CADMD) is limited due to its OTC listing and smaller market capitalization. Investors should conduct their own thorough due diligence and consider the risks associated with investing in OTC-listed companies. Key valuation metrics and growth considerations should be assessed based on available financial information and industry trends.
What are the main risks for CADMD?
The main risks for Chemesis International Inc. include regulatory uncertainties in the cannabis industry, intense competition, price volatility, capital constraints, and the risks associated with its OTC market listing. Regulatory changes could impact the company's operations and profitability. Intense competition could erode market share and margins. Price volatility in the cannabis market could affect revenue and profitability.
What are the key factors to evaluate for CADMD?
Evaluate CADMD on fundamentals, analyst consensus, and risk factors. Chemesis International Inc. presents a speculative investment opportunity within the high-growth cannabis sector. Not financial advice.
How frequently does CADMD data refresh on this page?
CADMD's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CADMD's recent stock price performance?
Chemesis International Inc. (CADMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Vertically integrated operations. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CADMD overvalued or undervalued right now?
Chemesis International Inc. (CADMD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CADMD before investing?
Before investing in Chemesis International Inc. (CADMD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market investments carry higher risks than exchange-listed stocks.
- Limited analyst coverage may impact the availability of information.